Join us:
January 10–12, 2022 in-personJanuary 17–19, 2022 virtually

Eric Aguiar
Partner at Aisling Capital LLC

Profile

Dr. Aguiar joined Aisling in 2016 and serves as a Partner. Prior to Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million healthcare-focused venture capital and growth equity fund, from 2007 to 2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a healthcare venture capital fund, from 2001 to 2007. He was CEO of Genovo, Inc., a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997. Dr. Aguiar currently serves as a director of BridgeBio Pharma and Invitae and as a board observer of PellePharm. His prior board service includes Amarin, CardioKine, Biohaven, Eidos (merged with BridgeBio), Metaphore (merged with ActivBiotics), Oriel Therapeutics (acquired by Novartis), SkinMedica, Virdante Pharmaceuticals (acquired by Momenta) and 3-D Pharmaceuticals. Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. Dr. Aguiar received his M.D. with honors from Harvard Medical School and his B.A. with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.

Agenda Sessions

  • Value creation and venture

    On Demand

Speakers at this event